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Abstract Venous stenting has been shown to effectively
treat iliofemoral venous obstruction with good short- and
mid-term results. The aim of this study was to investigate
long-term clinical outcome and stent patency. Twenty
patients were treated with venous stenting for benign dis-
ease at our institution between 1987 and 2005. Fifteen of
20 patients (15 female, mean age at time of stent implan-
tation 38 years [range 18–66]) returned for a clinical visit,
a plain X-ray of the stent, and a Duplex ultrasound. Four
patients were lost to follow-up, and one patient died
277 months after stent placement although a good clinical
result was documented 267 months after stent placement.
Mean follow-up after stent placement was 167.8 months
(13.9 years) (range 71 (6 years) to 267 months [22 years]).
No patient needed an additional venous intervention after
stent implantation. No signiﬁcant difference between the
circumference of the thigh on the stented side (mean
55.1 cm [range 47.0–70.0]) compared with the contralat-
eral thigh (mean 54.9 cm [range 47.0–70.0]) (p = 0.684)
was seen. There was a nonsigniﬁcant trend toward higher
ﬂow velocities within the stent (mean 30.8 cm/s [range
10.0–48.0]) and the corresponding vein segment on the
contralateral side (mean 25.2 cm/s [range 12.0–47.0])
(p = 0.065). Stent integrity was conﬁrmed in 14 of 15
cases. Only one stent showed a fracture, as documented on
x-ray, without any impairment of ﬂow. Venous stenting
using Wallstents showed excellent long-term clinical out-
come and primary patency rate.
Keywords Iliofemoral venous stent 
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Introduction
Benign iliofemoral venous occlusion is often difﬁcult to
treat. The main goal is to improve patient quality of life and
prevent chronic venous insufﬁciency (CVI), which may
lead to an inability to work [1].
In the past, different surgical techniques involving
venous bypass were used in cases of iliocaval venous
obstruction [2–4]. The main problem with bypass surgery
is its invasiveness and associated complications. The
reported outcomes are rather poor, with patency rates
between 54 and 84%. Therefore, this therapy option is
rarely used today [5].
In 1985, the ﬁrst use of a self-expanding stent was
described in the venous system of a dog [6]. Soon after-
ward the ﬁrst studies in humans were published [7–9].
Good short- and mid-term patency rates were reported in
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DOI 10.1007/s00270-010-9927-6these publications; however, the question of long-term
clinical outcome and stent patency remained unanswered.
The aim of the present study was to investigate clinical
outcome as well as stent patency and integrity after follow-
up[5 years.
Materials and Methods
The study was approved by our Institutional Review Board.
Written informed consent was obtained from all patients.
Patients
From January 1987 to October 2005, 20 patients were
admitted to our department for endovenous treatment of
benign iliofemoral stenosis or occlusion. Five patients were
excluded from further analysis. Four of these ﬁve patients
were lost to follow-up. One patient died 277 months
(23 years) after common iliac vein stent placement from a
cause unrelated to the venous stent. For this patient, the last
clinical visit 267 months (22 years) after stent placement
showed a good clinical outcome after iliac vein stenting
with no leg swelling. Fifteen patients (all female; mean age
at time of stent implantation 38 years [range 18–66]) were
included in the study. The etiology of obstruction was
iatrogenic stenosis of an iliofemoral vein in four cases
(patients no. 1, 2, 6, and 11) and stenosis of a venous
interposition graft of the superﬁcial femoral (patient no. 12)
and the common femoral veins (patient 14). Six patients
were treated with stents after thrombectomy for pelvic vein
thrombosis caused by May–Thurner syndrome (patients no.
3, 7, 8, 9, 10, and 15). Two patients were stented after
recanalization of a chronic postthrombotic obstruction of
the common and/or external iliac veins (patient no. 5 and
13). One patient was treated with common iliac vein stent
during treatment of an acute four-level thrombosis (patient
no. 4). Details concerning patient data are listed in Table 1.
Venous Intervention
The procedure was performed in the interventional suite
using either an ipsilateral retrograde percutaneous femoral
vein access in cases of a common or external iliac vein
obstruction or a crossover technique in cases of a common
femoral vein stenosis. In one patient with a long-standing
occlusion of the common and external iliac veins, a
transjugular approach had to be used (patient no. 5). In all
patients, self-expanding Wallstents (Boston Scientiﬁc,
Natick, MA) were used (details of stent dimensions are
listed in Table 1). We did not use other stent types. In the
cases of iatrogenic or postoperative stenoses as well as
chronic obstruction, a probatory test balloon angioplasty
was performed to evaluate adequate stent size. The
Wallstent was oversized by at least 1 mm. In cases of
insufﬁcient spontaneous self-expansion after placement,
the stent was dilated to the estimated diameter of the
treated vein. During the procedure, 5000 U heparin were
administrated intravenously. After stent placement all
patients were treated routinely with warfarin for 6 months.
Patients no. 4 and 13 (Table 1) had a factor V Leiden
mutation, which was treated with long-term therapy during
the entire observation period.
Follow-Up
Follow-up was conducted from October 2009 to November
2009. Follow-up included a clinical examination with
measurement of leg circumferences, Duplex ultrasound,
and x-ray of the stent. Fourteen of 15 follow-up examina-
tions were performed at the institution where the stents
were placed. In one case (patient no. 14), the follow-up
examination was performed in another hospital overseas.
Clinical Investigation
The patients were questioned for any intervention or sur-
gery concerning their veins after stent placement. Signs of
venous insufﬁciency, including varicosities and ulcers were
recorded. Maximum circumferences of the thighs and
calves were measured.
Duplex Ultrasound
The patients were examined using a state-of-the-art ultra-
sound scanner (Acuson Sequoia 512; Siemens, Munich,
Germany). 4- and 8-MHz probes were used. The presence
or absence of venous ﬂow through the stent was investi-
gated. In addition, maximum velocities within the stent and
the contralateral untreated vein were recorded. Further-
more, it was documented if there was venous reﬂux under
Valsalva maneuver.
X-Ray
Plain X-ray of the stent area was performed in anteropos-
terior view. In 14 patients, a ﬁlm of the pelvis was
obtained, and a ﬁlm of the thigh was taken in one patient
(patient no. 14). X-rays were analyzed for stent fractures on
a PACS system (Impax 4.2, Agfa) that allowed magniﬁed
and inverted views.
Statistical Analysis
Statistical analyses were performed using the statistical
program SPSS version 17 (SPSS version 17.0.1; SPSS,
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123Chicago, IL). The data were analyzed, and a mean of the
circumferences of the treated and nontreated legs, as well
as ﬂow measurements within the stent, were evaluated.
Wilcoxon signed-rank test was used for comparisons
within paired samples.
Results
Clinical Outcome
Mean follow-up after stent placement was 167.8 months
(13.9 years) (range 71–267 [6 to 22 years]). No patient
needed any additional intervention after stent implantation.
Two patients showed mild varicosis (patients no. 3 and
5), which had existed before venous stenting. In one
patient, severe venous insufﬁciency (patient no. 6) with
chronic venous ulcers was detected. This patient had severe
varicosity documented before the intervention.
No signiﬁcant difference (p = 0.684) between the cir-
cumference of the thigh on the stented side (mean 55.1 cm
[range 47.0–70.0]) and the contralateral thigh (mean
54.9 cm [range 47.0–70.0]) was found. There was a non-
signiﬁcant tendency toward a greater circumference of the
calf on the treated side (mean 37.7 cm [range 30.0–49.0])
compared with the nontreated side (mean 37.1 cm [range
31.0–48.0]) (p = 0.191).
Duplex Ultrasound
All stents were patent and had respiratory variation of
ﬂow. No stenosis or occlusion within the stent was seen.
There was a nonsigniﬁcant trend of higher ﬂow velocities
within the stent compared with the corresponding segment
of the contralateral side (p = 0.065). The median maxi-
mal velocity within the stent was 30.0 cm/s (range 10–
48), and the median maximal velocity of the contralataral
side was 20.0 cm/s (range 12–47). No patient showed
venous reﬂux under the Valsalva maneuver within the
stented segment.
X-Ray
Stent integrity, with normal stent morphology, was docu-
mented in 14 of 15 cases (Fig. 1). One stent showed a
single stent fracture (patient no. 14). We guess that the
reason for this fracture was a calciﬁed hematoma adjacent
to the stent, which resulted in chronic mechanical stress
(Fig. 2A–F). It is remarkable that even stents placed in the
common femoral vein directly over the hip joint (patients
no. 1 and 11 through 13) showed no fracture after 83 to
222 months later (Fig. 3A, B).
Discussion
Our data suggest that stenting of benign iliofemoral venous
obstruction has a good long-term clinical outcome with
excellent stent patency. After a mean follow-up of
167.8 months (13.9 years), no additional venous interven-
tion was needed in any patient. There was no signiﬁcant leg
swelling of the stented extremity compared with the con-
tralateral side.
Since its introduction in the mid-1980 s, venous stenting
has become a widely accepted treatment option [10–14].
Venous stenting has replaced surgical techniques, such as
the Palma operation or the axial bypass technique for
venous obstruction [15]. Not only is surgery more invasive
than stenting, it also shows low patency rates between 44%
and 85% [16].
Few reports about the mid- and long-term results after
stenting of benign iliocaval obstructions [17–22] have
shown patency rates approaching 100% without any stent
fractures or other stent-related complications.
Our study focused on long-term outcomes[5 years. The
results conﬁrm excellent long-term result, with a patency
rate of 100%, which corresponds to the good clinical out-
come as measured by the lack of leg swelling.
Stent integrity has generally not been assessed in the
venous system in the published literature [17–22] com-
pared with the arterial system, in which stent fractures are
of concern, particularly in the lower extremity [23, 24]. We
encountered only one stent fracture (6.7%) in a special
situation, i.e., the stent was placed in the superﬁcial
Fig. 1 Shows X-ray of the pelvis, including a magniﬁed view
demonstrating the integrity of the stent in the left common iliac vein
13 years after placement for acute thrombosis due to a May–Thurner
syndrome
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123Fig. 2 Serial venograms during a follow-up period of 22 years
(patient no. 14) after a stab wound injury of the right superﬁcial
femoral vein, which was treated with a venous interposition graft,
resulting in stenosis of the femoral vein. A Venogram shows severe
stenosis corresponding to the venous interposition graft. B Venogram
taken after placement of two 14 9 70-mm Wallstents in the
superﬁcial femoral vein. C Venogram taken 4 years later shows
new soft-tissue calciﬁcation adjacent to the patent stent (arrow),
which was interpreted as a calciﬁed hematoma or myositis ossiﬁcans.
The stent is intact at follow-up of 6, 8, and 22 years. D, F A stent
fracture can be noticed (curved arrow), which remained mostly
unchanged over the years, with no signs of ﬂow impairment or
clinical signs of leg swelling. The likely cause of the stent fracture can
be identiﬁed as the pointed part of the calciﬁcation (arrow) interfering
with the stent
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123femoral vein (patient no. 14). During follow-up, soft-tissue
calciﬁcations developed lateral to the stent, which led to
focal stent fracture after 6 years. The stent remained patent
without any impairment of ﬂow, despite the fracture, dur-
ing a follow-up of 22 years.
Interestingly, no fractures were seen in the four stents
placed in the common femoral vein across the hip joint.
One patient (patient no. 15) with a common iliac stent had
a normal pregnancy without any damage to the stent.
In the present study, patients were treated with warfarin
for 6 months. Thereafter, no further anticoagulation was
given routinely. Because no thrombosis occurred during
our study, long-term anticoagulation did not seem neces-
sary. The ability to stop anticoagulation is helpful because
long-term anticoagulation during a period of years has its
own risks [25].
Our study has several limitations. First, we only include
a small study group, especially in the age group\50 years.
Therefore, the long-term results should be interpreted with
caution. The second limitation is the use a single device
type (Wallstent), and the third limitation is the variety of
underlying causes for venous obstruction.
In conclusion, venous stenting with Wallstents showed
an excellent patency rate with good clinical outcomes
between 71 months (6 years) and 267 months (22 years).
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